Golden
TG Therapeutics

TG Therapeutics

A biopharmaceutical company developing treatments for B-cell malignancies and autoimmune diseases

All edits

Edits on 27 Aug 2019
Will Suter
Will Suter approved a suggestion from Golden's AI on 27 Aug 2019 2:45 am
Edits made to:
Article (+19/-19 characters)

Article

TG-1101, also known as Ublituximab, is a monoclonal antibodymonoclonal antibody that targets a specific epitope on the B-lymphocyte CD20 antigen. It has been bioengineered to deliver enhanced clinical activity and potency. The product is aimed at treating B-cell proliferative disorders including, Non-Hodgkin's Lymphoma (NHL) and Cronic Lymphocytic Leukemia (CLL). It has also shown effectiveness against autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), as well as the neurological disorder, Multiple Sclerosis (MS). Ublituximab is in Phase 3 clinical development for patients with hematologic malignancies and patients with multiple sclerosis.

Will Suter
Will Suter approved a suggestion from Golden's AI on 27 Aug 2019 2:45 am
Edits made to:
Article (+4/-4 characters)

Article

TG-1101, also known as Ublituximab, is a monoclonal antibody that targets a specific epitope on the B-lymphocyte CD20CD20 antigen. It has been bioengineered to deliver enhanced clinical activity and potency. The product is aimed at treating B-cell proliferative disorders including, Non-Hodgkin's Lymphoma (NHL) and Cronic Lymphocytic Leukemia (CLL). It has also shown effectiveness against autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), as well as the neurological disorder, Multiple Sclerosis (MS). Ublituximab is in Phase 3 clinical development for patients with hematologic malignancies and patients with multiple sclerosis.

Carla Faraguna
Carla Faraguna edited on 26 Aug 2019 5:57 pm
Edits made to:
Article (+2753 characters)

Article



TG-1801 is the first treatment that targets both CD19 and CD47. CD19 is a B cell-specific marker widely expressed in B cell malignant tumors, while CD47 is expressed in both healthy and tumor cells, transmitting the "don't eat me" signal. In order to escape macrophage-mediated phagocytosis, CD47 is widely expressed in normal cells, including red blood cells and platelets. Co-targeting CD47 and CD19,TG-1801 has the potential to overcome the limitations of existing CD47 targeting therapy and avoid the side effects of indiscriminate blocking of CD47 on healthy cells.



TG has two therapies into III clinical development: (1) ublituximab, a new type of glycosylated anti-CD20 monoclonal antibody, Targeting specific epitopes of CD20 antigen on mature B lymphocytes; (2) umbralisib, an oral, daily, new generation of PI3K δ inhibitors, can uniquely inhibit CK1- ε, which may enable it to overcome some tolerance problems associated with the first generation of PI3K δ inhibitors.



The combination of ublituximab, umbralisib and U2 is in the clinical stage of III in the treatment of hematological malignant tumors, in addition, the treatment of multiple sclerosis with ublituximab has also been in the clinical stage of III. Just recently, the company pushed its anti-PD-1 monoclonal antibody TG-1501, a covalently bound BTK inhibitor TG-1701, into Phase I clinical practice.

...

TG-1801

TG-1801 is the first treatment that targets both CD19 and CD47. CD19 is a B cell-specific marker widely expressed in B cell malignant tumors, while CD47 is expressed in both healthy and tumor cells, transmitting the "don't eat me" signal. In order to escape macrophage-mediated phagocytosis, CD47 is widely expressed in normal cells, including red blood cells and platelets. Co-targeting CD47 and CD19, TG-1801 has the potential to overcome the limitations of existing CD47 targeting therapy and avoid the side effects of indiscriminate blocking of CD47 on healthy cells.



TG has two therapies into III clinical development: (1) ublituximab, a new type of glycosylated anti-CD20 monoclonal antibody, Targeting specific epitopes of CD20 antigen on mature B lymphocytes; (2) umbralisib, an oral, daily, new generation of PI3K δ inhibitors, can uniquely inhibit CK1- ε, which may enable it to overcome some tolerance problems associated with the first generation of PI3K δ inhibitors.



The combination of ublituximab, umbralisib and U2 is in the clinical stage of III in the treatment of hematological malignant tumors, in addition, the treatment of multiple sclerosis with ublituximab has also been in the clinical stage of III. Just recently, the company pushed its anti-PD-1 monoclonal antibody TG-1501, a covalently bound BTK inhibitor TG-1701, into Phase I clinical practice.

Edits on 12 Jun 2019
Golden AI
Golden AI edited on 12 Jun 2019 10:42 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:52 am
Edits made to:
Infobox (+2 properties)
Edits on 1 Apr 2019
Dawson Sewell
Dawson Sewell edited on 1 Apr 2019 2:11 pm
Edits made to:
Infobox (+7 properties)
Article (+297/-59 characters)

Article

TG Therapeutics is a publicly owned biopharmaceutical company headquartered in New YorkNew York City, New York that was founded in 1993 by Michael Sean Weiss and Laurence H. Shaw. It focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company's product pipeline has two therapies in clinical development, TG-1101 and TG-1202.



Products

TG-1101

...



TG-1202

...



Preclinical studies

TG Therapeutics has several other products in its pipeline, which are at various stages of preclicalpreclinical studies:

IRAK4

IRAK4

...



Anti-PD-L1 & Anti-GITR

Anti-PD-L1 & Anti-GITR

...



TG-1601

TG-1601

...



TG-1701

TG-1701

...

Funding

Post-IPO Equity

On February 29, 2012 TG Therapeutics announced raising $25 million in Post-IPO capital. 

Infobox

Edits on 7 Mar 2019
Sameeha Sulaiman
Sameeha Sulaiman edited on 7 Mar 2019 12:45 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 20 Feb 2019
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 20 Feb 2019 4:09 am
Edits made to:
Infobox (+7 properties)

Infobox

Stock exchange
Stock symbol
TGTX
Place of incorporation
Headquarters
IRS Number
363,898,269
CIK Number
1,001,316
SIC Code
2,834
Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:15 pm
Edits made to:
Infobox (+1/-1 properties)

Infobox

Edits on 9 Jan 2019
Golden AI
Golden AI edited on 9 Jan 2019 10:04 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 4 Jan 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 4 Jan 2019 5:54 pm
Edits made to:
Article (+5/-5 characters)

Article

IRAK4IRAK4

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 4 Jan 2019 5:54 pm
Edits made to:
Article (+17/-17 characters)

Article

A key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with Waldensrom's MacroglobulinemiaMacroglobulinemia, a rare B-cell cancer, as well as in some specific cases of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. IRAK4 is also key in regulating immune and inflammatory processes, suggesting that it may be useful in treating autoimmune related disorders.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 4 Jan 2019 5:53 pm
Edits made to:
Article (+15/-15 characters)

Article

TG-1701 is an orally available BTK inhibitor. Targeting BTk with small molecule inhibitors has demonstrated effectiveness as a treatment option for B-cell lymphomas and autoimmune diseases. The product is in Phase 1 clinical trialsclinical trials in China.

Edits on 4 Jan 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 4 Jan 2019 2:35 am
Edits made to:
Article (+28/-28 characters)

Article

TG-1101, also known as Ublituximab, is a monoclonal antibody that targets a specific epitope on the B-lymphocyte CD20 antigen. It has been bioengineered to deliver enhanced clinical activity and potency. The product is aimed at treating B-cell proliferative disorders including, Non-Hodgkin's Lymphoma (NHL) and Cronic Lymphocytic Leukemia (CLL). It has also shown effectiveness against autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus ErythematosusSystemic Lupus Erythematosus (SLE), as well as the neurological disorder, Multiple Sclerosis (MS). Ublituximab is in Phase 3 clinical development for patients with hematologic malignancies and patients with multiple sclerosis.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 3 Jan 2019 8:37 pm
Edits made to:
Article (+11/-11 characters)

Article

TG-1101, also known as UblituximabUblituximab, is a monoclonal antibody that targets a specific epitope on the B-lymphocyte CD20 antigen. It has been bioengineered to deliver enhanced clinical activity and potency. The product is aimed at treating B-cell proliferative disorders including, Non-Hodgkin's Lymphoma (NHL) and Cronic Lymphocytic Leukemia (CLL). It has also shown effectiveness against autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), as well as the neurological disorder, Multiple Sclerosis (MS). Ublituximab is in Phase 3 clinical development for patients with hematologic malignancies and patients with multiple sclerosis.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 3 Jan 2019 8:36 pm
Edits made to:
Article (+19/-19 characters)

Article

TG Therapeutics is a publicly owned biopharmaceutical company headquartered in New York. It focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseasesautoimmune diseases. The company's product pipeline has two therapies in clinical development, TG-1101 and TG-1202.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 3 Jan 2019 8:35 pm
Edits made to:
Article (+18/-18 characters)

Article

TG-1101, also known as Ublituximab, is a monoclonal antibody that targets a specific epitope on the B-lymphocyte CD20 antigen. It has been bioengineered to deliver enhanced clinical activity and potency. The product is aimed at treating B-cell proliferative disorders including, Non-Hodgkin's Lymphoma (NHL) and Cronic Lymphocytic Leukemia (CLL). It has also shown effectiveness against autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), as well as the neurological disorder, Multiple SclerosisMultiple Sclerosis (MS). Ublituximab is in Phase 3 clinical development for patients with hematologic malignancies and patients with multiple sclerosis.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 3 Jan 2019 8:34 pm
Edits made to:
Article (+20/-20 characters)

Article

TG-1101, also known as Ublituximab, is a monoclonal antibody that targets a specific epitope on the B-lymphocyte CD20 antigen. It has been bioengineered to deliver enhanced clinical activity and potency. The product is aimed at treating B-cell proliferative disorders including, Non-Hodgkin's Lymphoma (NHL) and Cronic Lymphocytic Leukemia (CLL). It has also shown effectiveness against autoimmune diseases such as Rheumatoid ArthritisRheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), as well as the neurological disorder, Multiple Sclerosis (MS). Ublituximab is in Phase 3 clinical development for patients with hematologic malignancies and patients with multiple sclerosis.

Edits on 3 Jan 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 3 Jan 2019 1:25 am
Edits made to:
Article (+5/-5 characters)

Article

TG-1701 is an orally available BTK inhibitor. Targeting BTk with small molecule inhibitors has demonstrated effectiveness as a treatment option for B-cell lymphomas and autoimmune diseases. The product is in Phase 1 clinical trials in ChinaChina.

Sameeha Sulaiman
Sameeha Sulaiman edited on 2 Jan 2019 8:53 pm
Edits made to:
Article (+1625/-183 characters)

Article

  • IRAK4 - a key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with Waldensrom's

IRAK4

A key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with Waldensrom's Macroglobulinemia, a rare B-cell cancer, as well as in some specific cases of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. IRAK4 is also key in regulating immune and inflammatory processes, suggesting that it may be useful in treating autoimmune related disorders.



Anti-PD-L1 & Anti-GITR

Anti-PD-L1 antibodies target programmed cell death ligand 1 (PD-L1). They are designed to block signals permitting effector T-cells to attack cancer. Anti-GITR antibodies target glucocorticoid-induced tumor necrosis factor receptor related protein (GITR). It has shown to amplify the antitumor immune responses in animal models. Pre-clinical research on therapies using a combination of these two antibodies have yielded positive results. The Anti-PD-L1 monoclonal antibody has been brought into Phase 1 of clinical development. 



TG-1601

TG-1601 is a small molecule that binds to the epigenetic BET family of bromodomain-containing proteins and inhibits their binding to chromatin. It can increase the sensitivity of tumors to chemotherapy or specific standard of care by resetting the genome in tumor cells. TG-1601 is in pre-clinical development and is being tested in various IND-enabling studies.

...

TG-1701

TG-1701 is an orally available BTK inhibitor. Targeting BTk with small molecule inhibitors has demonstrated effectiveness as a treatment option for B-cell lymphomas and autoimmune diseases. The product is in Phase 1 clinical trials in China.